UCBJYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:45):

Stats
本日の出来高	36 599.00
平均出来高	12 804.00
時価総額	25.23B
Last Dividend	$0.726 ( 2023-05-01 )
Next Dividend	$0 ( N/A )
P/E	70.72
ATR14	$0.185 (0.28%)

UCB SA 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

UCB SA 財務諸表

Annual	2023
収益:	$5.25B
総利益:	$3.55B (67.50 %)
EPS:	$1.810

FY	2023
収益:	$5.25B
総利益:	$3.55B (67.50 %)
EPS:	$1.810

FY	2022
収益:	$5.52B
総利益:	$3.84B (69.64 %)
EPS:	$2.20

FY	2021
収益:	$5.78B
総利益:	$4.34B (75.11 %)
EPS:	$5.60

Financial Reports:

No articles found.

UCB SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.726 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

UCB SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.90 - Stable (2.01%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.663	2013-05-02
Last Dividend	$0.726	2023-05-01
Next Dividend	$0	N/A
Payout Date	2023-05-18
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$7.46	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.90
Div. Directional Score	8.72	--

Next Divdend (Est)
(2025-03-31)

$0.745 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
OVCHY	Ex Dividend Junior	2023-08-15	Annually	0.00%
DURYY	Ex Dividend Junior	2023-05-15	Annually	0.00%
TTNDY	Ex Dividend Knight	2023-08-28	Semi-Annually	0.00%
JMSB	Ex Dividend Junior	2023-06-26	Annually	0.00%
BORT	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
RGPCF	Ex Dividend Junior	2023-09-01	Semi-Annually	0.00%
FBPI	Ex Dividend Knight	2023-08-30	Quarterly	0.00%
VTKLY	Ex Dividend Knight	2023-07-20	Semi-Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CKHGY	Ex Dividend Knight	2023-05-11	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0656	1.500	8.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0331	1.200	8.90	10.00	[0 - 0.3]
returnOnEquityTTM	0.0571	1.500	-0.477	-0.715	[0.1 - 1]
payoutRatioTTM	0.490	-1.000	5.10	-5.10	[0 - 1]
currentRatioTTM	1.317	0.800	8.42	6.73	[1 - 3]
quickRatioTTM	0.839	0.800	9.77	7.81	[0.8 - 2.5]
cashRatioTTM	0.329	1.500	9.28	10.00	[0.2 - 2]
debtRatioTTM	0.196	-1.500	6.74	-10.00	[0 - 0.6]
interestCoverageTTM	4.50	1.000	9.45	9.45	[3 - 30]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0.338	-1.500	8.65	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.648	1.000	2.54	2.54	[0.2 - 0.8]
operatingProfitMarginTTM	0.120	1.000	9.59	9.59	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.328	1.000	9.29	9.29	[0.2 - 2]
assetTurnoverTTM	0.505	0.800	9.97	7.97	[0.5 - 2]
Total Score				12.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	22.92	1.000	7.79	0	[1 - 100]
returnOnEquityTTM	0.0571	2.50	-0.306	-0.715	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	2.34	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
payoutRatioTTM	0.490	1.500	5.10	-5.10	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.127	1.000	9.32	0	[0.1 - 0.5]
Total Score				4.90

UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.